eXoZymes Reports Q4 and FY25 Financials, Plans Next Financing Round

eXoZymes Inc. provides an update on operations through the fiscal year ended December 31, 2025, with a focus on execution, building differentiated assets and capabilities, and advancing high-value product programs. Operating expenses increased to $9.72 million, and net loss was $9.16 million. The company ended the year with $3.04 million in cash and cash equivalents, supporting continued execution. The company is preparing for its next phase of financing while maintaining a capital-efficient operating model.